Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dynavax Technologies Corporation

http://www.dynavax.com

Latest From Dynavax Technologies Corporation

Sinovac Real-World Data In Brazil Shed Fresh Light On China COVID Vaccine Efficacy Debate

Sinovac’s COVID-19 vaccine has an efficacy rate of 50% in one hard-hit region of Brazil, a study finds, which could fuel fresh doubts over the efficacy of Chinese vaccines and raise the urgency to change current vaccination strategy.

Real-World Evidence Coronavirus COVID-19

Sinovac Real World Data Shed Fresh Light On China COVID Vaccine Efficacy Debate

New real world data for Sinovac’s COVID-19 vaccine from hard-hit Brazil could fuel fresh doubts over the efficacy of Chinese vaccines, but also raise the urgency to change current vaccination strategy.

Coronavirus COVID-19 Vaccines

China COVID-19 Vaccines Efficacy Inadequate? Hot Debate, Variant Worries Swirl

China's regulators and spin doctors rush to remedy a comment from the nation’s top infectious disease official about the “not high” protection rate for its COVID-19 vaccines, amid debate over speedy development using mature technologies and doubts over protection in seniors. A slow roll-out is already presenting challenges to meeting an official 40% target.

China Coronavirus COVID-19

Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas

Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.

Financing Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
  • Other Names / Subsidiaries
    • Symphony Dynamo, Inc. (SDI)
UsernamePublicRestriction

Register